← FDA DRUG APPROVALS

FDA ANDA · ANDA212367

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

Sponsor: PADAGIS ISRAEL

APPLICATION
ANDA212367
TYPE
ANDA
ORIGINAL APPROVAL
2020-09-11
LATEST ACTION
2020-09-11
ROUTE
TOPICAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE 0.064%, CALCIPOTRIENE 0.005% · SUSPENSION · TOPICAL

Approval history

2020-09-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →